Literature DB >> 25352235

Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency.

H L Storr1, R Prasad2, I K Temple3, L A Metherell2, M O Savage2, J M Walker4.   

Abstract

PURPOSE: The IGFALS gene encodes the acid-labile subunit (ALS) protein, which regulates circulating IGF-1. Human IGFALS mutations cause growth hormone insensitivity (GHI) associated with ALS, IGF-1 and IGFBP-3 deficiencies and mild to moderate postnatal growth impairment (height SDS -2 to -4). Prenatal growth impairment is not a recognised feature of this disorder, but heterozygous carriers may show an intermediate phenotype.
METHODS: We report a family of five subjects, including three children born small for gestational age, who were investigated for IGFALS gene mutations.
RESULTS: The proband, an 8.7 years female with pre- and postnatal growth failure (BW SDS -3.04, Ht SDS -3.86) and biochemical features of GHI, had a homozygous mutation of IGFALS, c.401T>A; p.L134Q. Her 6.1 years brother (BW SDS -2.11, Ht SDS -2.0) had the same homozygous IGFALS mutation. Both parents [adult height SDS -1.76 (father) and -1.82 (mother)] and her 2.7 years sister (BW SDS -2.60, Ht SDS -2.04) were heterozygous for the IGFALS mutation.
CONCLUSION: Significant phenotypic heterogeneity was observed between family members, in particular varying degrees of prenatal growth retardation were present in the three siblings, which may have contributed to the variation in the postnatal growth phenotype.

Entities:  

Keywords:  Acid-labile subunit (ALS); Growth hormone insensitivity (GHI); IGFALS mutation; Short stature; Small for gestational age (SGA)

Mesh:

Substances:

Year:  2014        PMID: 25352235     DOI: 10.1007/s40618-014-0195-1

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

Review 1.  The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system.

Authors:  Y R Boisclair; R P Rhoads; I Ueki; J Wang; G T Ooi
Journal:  J Endocrinol       Date:  2001-07       Impact factor: 4.286

2.  Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene.

Authors:  Horacio M Domené; Sonia V Bengolea; Alicia S Martínez; M Gabriela Ropelato; Patricia Pennisi; Paula Scaglia; Juan J Heinrich; Héctor G Jasper
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

Review 3.  Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse.

Authors:  H M Domené; S V Bengolea; H G Jasper; Y R Boisclair
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

4.  Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system.

Authors:  I Ueki; G T Ooi; M L Tremblay; K R Hurst; L A Bach; Y R Boisclair
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia.

Authors:  M S Lewitt; F P Scott; N M Clarke; R C Baxter
Journal:  Prog Growth Factor Res       Date:  1995

6.  Expression and protein content of IGF-I and IGF-I receptor in placentas from small, adequate and large for gestational age newborns.

Authors:  G Iñiguez; C A González; F Argandoña; E Kakarieka; M C Johnson; F Cassorla
Journal:  Horm Res Paediatr       Date:  2010-04-14       Impact factor: 2.852

7.  Acid-labile subunit (ALS) gene expression and protein content in human placentas: differences according to birth weight.

Authors:  Germán Iñiguez; Felipe Argandoña; Pablo Medina; Carolina González; Sebastián San Martín; Elena Kakarieka; M Cecilia Johnson; Fernando Cassorla
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

8.  Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit.

Authors:  H A van Duyvenvoorde; M J E Kempers; Th B Twickler; J van Doorn; W J Gerver; C Noordam; M Losekoot; M Karperien; J M Wit; A R M M Hermus
Journal:  Eur J Endocrinol       Date:  2008-05-07       Impact factor: 6.664

9.  Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia.

Authors:  Karen E Heath; Jesús Argente; Vicente Barrios; Jesús Pozo; Francisca Díaz-González; Gabriel A Martos-Moreno; María Caimari; Ricardo Gracia; Angel Campos-Barros
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 10.  Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences.

Authors:  Horacio M Domené; Vivian Hwa; Jesús Argente; Jan M Wit; Jaan M Wit; Cecilia Camacho-Hübner; Héctor G Jasper; Jesús Pozo; Hermine A van Duyvenvoorde; Shoshana Yakar; Olga V Fofanova-Gambetti; Ron G Rosenfeld
Journal:  Horm Res       Date:  2009-09-01
View more
  3 in total

Review 1.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

2.  A Novel Homozygous Mutation of the Acid-Labile Subunit (IGFALS) Gene in a Male Adolescent

Authors:  Şükran Poyrazoğlu; Vivian Hwa; Firdevs Baş; Andrew Dauber; Ron Rosenfeld; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-02-05

Review 3.  The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders.

Authors:  Werner F Blum; Abdullah Alherbish; Afaf Alsagheir; Ahmed El Awwa; Walid Kaplan; Ekaterina Koledova; Martin O Savage
Journal:  Endocr Connect       Date:  2018-05-03       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.